Multimodal Therapy Approaches for NUT Carcinoma by Dual Combination of Oncolytic Virus Talimogene Laherparepvec with Small Molecule Inhibitors
Viruses · 2024
DOI: 10.3390/v16050775 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2024. Verfasst von Stavros Sotiriadis und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology and Pneumology, Virotherapy Center Tübingen (VCT), Medical University Hospital, 72076 Tübingen, Germany. Hauptthemen laut MEDLINE: Oncolytic Viruses, Oncolytic Virotherapy, Biological Products. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Interdisziplinäres Zentrum für Klinische Forschung (IZKF, Interdisciplinary Center for Clinical Research).
Abstract (Originalsprache)
NUT (nuclear-protein-in-testis) carcinoma (NC) is a highly aggressive tumor disease. Given that current treatment regimens offer a median survival of six months only, it is likely that this type of tumor requires an extended multimodal treatment approach to improve prognosis. In an earlier case report, we could show that an oncolytic herpes simplex virus (T-VEC) is functional in NC patients. To identify further combination partners for T-VEC, we have investigated the anti-tumoral effects of T-VEC and five different small molecule inhibitors (SMIs) alone and in combination in human NC cell lines. Dual combinations were found to result in higher rates of tumor cell reductions when compared to the respective monotherapy as demonstrated by viability assays and real-time tumor cell growth monitoring. Interestingly, we found that the combination of T-VEC with SMIs resulted in both stronger and earlier reductions in the expression of c-Myc, a main driver of NC cell proliferation, when compared to T-VEC monotherapy. These results indicate the great potential of combinatorial therapies using oncolytic viruses and SMIs to control the highly aggressive behavior of NC cancers and probably will pave the way for innovative multimodal clinical studies in the near future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology and Pneumology, Virotherapy Center Tübingen (VCT), Medical University Hospital, 72076 Tübingen, Germany.
- German Cancer Consortium (DKTK), Partner Site Tübingen, a Partnership between DKFZ and University Hospital Tübingen, 72076 Tübingen, Germany.
ORCID-Profile: Julia Beil
Förderung
- Deutsche Forschungsgemeinschaft
- Interdisziplinäres Zentrum für Klinische Forschung (IZKF, Interdisciplinary Center for Clinical Research)
Zitieren
APA
Sotiriadis, S., Beil, J., Berchtold, S., Smirnow, I., Schenk, A., & Lauer, U. M. (2024). Multimodal Therapy Approaches for NUT Carcinoma by Dual Combination of Oncolytic Virus Talimogene Laherparepvec with Small Molecule Inhibitors. Viruses. https://doi.org/10.3390/v16050775
Vancouver
Sotiriadis S, Beil J, Berchtold S, Smirnow I, Schenk A, Lauer UM. Multimodal Therapy Approaches for NUT Carcinoma by Dual Combination of Oncolytic Virus Talimogene Laherparepvec with Small Molecule Inhibitors. Viruses. 2024. doi:10.3390/v16050775
BibTeX
@article{Sotiriadis2024,
author = {Sotiriadis, Stavros and Beil, Julia and Berchtold, Susanne and Smirnow, Irina and Schenk, Andrea and Lauer, Ulrich M},
title = {Multimodal Therapy Approaches for NUT Carcinoma by Dual Combination of Oncolytic Virus Talimogene Laherparepvec with Small Molecule Inhibitors},
journal = {Viruses},
year = {2024},
doi = {10.3390/v16050775}
}
EUVIMED